Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
In 2016, the American Academy of Ophthalmology (AAO) changed the recommended dosing of hydroxychloroquine from 6.5 mg/kg to less than 5 mg/kg. However, it is not clear that the lower prescribed dose of hydroxychloroquine will have the same efficacy for SLE activity or the same protective role against cardiovascular risk factors and thrombosis. We addressed the frequency of hydroxychloroquine retinopathy and the role of hydroxychloroquine blood levels to identify those at greater future risk of retinopathy. 537 SLE patients in a large clinical cohort were repeatedly assessed for hydroxychloroquine blood levels and tested for hydroxychloroquine retinopathy. We assessed the risk of retinopathy by clinical characteristics and levels of hydroxychloroquine in the blood. The overall frequency of retinopathy was 4.3% (23/537). There was 1% risk of retinopathy in the first 5 years, 1.8% from 6 to 10 years, 3.3% from 11 to 15 years, 11.5% from 16 to 20 years, and 8.0% after 21 years of use. We found that older patients (p<0.0001), higher body mass index (p=0.0160 for trend) and longer duration of hydroxychloroquine intake (p=0.0024 and p=0.0006 for trend) were associated with higher risk of hydroxychloroquine toxicity. Higher hydroxychloroquine blood levels predicted later hydroxychloroquine retinopathy (p=0.0124 and p=0.0340 for mean and maximum HCQ blood levels respectively). Our data prove the utility of hydroxychloroquine blood levels in predicting retinopathy. This would allow clinicians to either decrease dose or increase monitoring in those with high blood levels.